Vaccine Adjuvants Market Outlook 2031:
The global vaccine adjuvants market size was valued at USD 1.30 Billion in 2022 and is projected to reach USD 1.54 Billion by 2031, expanding at a CAGR of 1.9% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising incidences of cervical cancer and other infectious diseases such as tuberculosis, human papillomavirus, and HIV.
Adjuvants are immune supporters simultaneously with antigens in order to boost vaccine efficiency. Adjuvants need was established with vaccine after discovery of highly purified, safe but less synthetic antigens, synthetic antigens, immunogenic through innovation in recombinant DNA technology.
Adjuvants affect the immune system in various ways: to modulate humoral responses, to increase the immunogenicity of weak antigens, to enhance speed of immune response, to stimulate cell-mediated immunity, and to improve induction of mucosal immunity.
Additionally, increasing focus on the long term effect of immunization for existing diseases and newly found COVID-19 vaccine are expected to fuel demand for adjuvants. The need of adjuvant development of these innovative and effective products has increased due to the insufficient immunogenicity of vaccine antigens.
Major players are actively engaged in the research and development of adjuvants to treat diseases. There are certain products that are under the clinical trials namely ISCOM & ISCOMMATRIX, AS01, AS02, and the potential development of these drugs are key aspects for the market growth.
Moreover, one of the major dimension for the market can be the expansion of awareness campaigns from government agencies and organizations. For instance, a program was initiated by National Institute of Allergy and Infectious Diseases for adjuvants for human use.
Vaccine Adjuvants Market Trends, Drivers, Restraints, and Opportunities
- Rising incidences of chronic diseases such as tuberculosis, human papillomavirus, HIV, and cervical cancer are expected to fuel the demand for adjuvants.
- Increasing focus on the long term effect of immunization for existing diseases and newly found COVID-19 is expected to accelerate demand for adjuvants.
- Growing use of synthetic vaccines and rising awareness of regular immunization for disease prevention are expected to boost the market growth in the coming years.
- Favorable government initiatives and policies for encouraging the development of effective vaccine for the treatment of serious diseases is anticipated to spur the market revenue.
Scope of Vaccine Adjuvants Market Report
The report on the global vaccine adjuvants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Vaccine Adjuvants Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Types (Adjuvant Emulsion, Particulate, Combination, Pathogen, and Others), Routes of Administration (Intradermal, Intranasal, Intramuscular, Oral, and Others), and Applications (Infectious Disease, Cancer, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Novavax, Inc.; SPI Pharma, Inc.; Agenus, Inc.; Adjuvance Technologies, Inc; CSL Limited; InvivoGen; Brenntag Biosector; and GlaxoSmithKline plc.
|
Vaccine Adjuvants Market Segment Insights
Particulate segment is expected to grow at a rapid pace
Based on types, the global vaccine adjuvants market is divided into adjuvant emulsion, particulate, combination, pathogen, and others. The particulate segment is expected to grow at a rapid pace of the market in the coming years as these are most commonly used adjuvants for hepatitis B and HPV vaccines.
However, the pathogen segment is anticipated to account for a key market share during the forecast period as this is cost-effective and easily available in the market.
Intramuscular segment is projected to expand at a considerable CAGR
On the basis of routes of administration, the market is segregated into intradermal, intranasal, intramuscular, oral, and others. The intramuscular segment is projected to expand at a considerable CAGR during the projected period due to the high efficiency of these to support vaccines.
Meanwhile, the intradermal segment is anticipated to hold a large market share during the forecast period owing to longer absorption and duration of action as compared to other adjuvants.
Infectious disease segment is expected to register a robust growth rate
Based on applications, the global vaccine adjuvants market is divided into infectious disease, cancer, and others. The infectious disease segment accounted for a key share of the market in 2020 and is expected to register a robust growth rate in the coming years owing to large pipeline of products.
On the other hand, the cancer segment is anticipated to grow significantly during the forecast period due to high number of incidences and ongoing research and development activities for targeted therapy.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market during the projected period owing to rise in investments in research and development activities and in fatal diseases in the region.
The market of Asia Pacific, however, is expected to exhibit a considerable growth rate during the forecast period due to improving healthcare facilities and availability of medicines in the region.
Segments
The global vaccine adjuvants market has been segmented on the basis of
Types
- Adjuvant Emulsion
- Particulate
- Combination
- Pathogen
- Others
Routes of Administration
- Intradermal
- Intranasal
- Intramuscular
- Oral
- Others
Applications
- Infectious Disease
- Cancer
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global vaccine adjuvants market are Novavax, Inc.; SPI Pharma, Inc.; Agenus, Inc.; Adjuvance Technologies, Inc; CSL Limited; InvivoGen; Brenntag Biosector; and GlaxoSmithKline plc. The main market players are continuously engaged in the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations. For instance, GSK collaborated with Exscientia.ai for developing new drugs in July 2017.
Request For Customization
Enquiry Before Buying
Speak With Analyst
